DNA methylation based biomarkers in colorectal cancer: A systematic review

详细信息    查看全文

• 作者：Kevin Lam¹ ; Kathy Pan¹ ; Janneke Fiona Linnekamp ; Jan Paul Medema ; Raju Kandimalla ; ^{r.kandimalla@amc.uva.nl" class="auth_mail" title="E-mail the corresponding author} ; ^{raju.kandimalla@bswhealth.org" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Colorectal cancer ; DNA methylation ; Diagnosis ; Prognosis ; Population screening ; Biomarkers
• 刊名：Biochimica et Biophysica Acta (BBA)-Reviews on Cancer
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：1866
• 期：1
• 页码：106-120
• 全文大小：769 K

文摘

Since genetic and epigenetic alterations influence the development of colorectal cancer (CRC), huge potential lies in the use of DNA methylation as biomarkers to improve the current diagnosis, screening, prognosis and treatment prediction. Here we performed a systematic review on DNA methylation-based biomarkers published in CRC, and discussed the current state of findings and future challenges. Based on the findings, we then provide a perspective on future studies. Genome-wide studies on DNA methylation revealed novel biomarkers as well as distinct subgroups that exist in CRC. For diagnostic purposes, the most independently validated genes to study further are VIM, SEPT9, ITGA4, OSM4, GATA4 and NDRG4. These hypermethylated biomarkers can even be combined with LINE1 hypomethylation and the performance of markers should be examined in comparison to FIT further to find sensitive combinations. In terms of prognostic markers, myopodin, KISS1, TMEFF2, HLTF, hMLH1, APAF1, BCL2 and p53 are independently validated. Most prognostic markers published lack both a multivariate analysis in comparison to clinical risk factors and the appropriate patient group who will benefit by adjuvant chemotherapy. Methylation of IGFBP3, mir148a and PTEN are found to be predictive markers for 5-FU and EGFR therapy respectively. For therapy prediction, more studies should focus on finding markers for chemotherapeutic drugs as majority of the patients would benefit. Translation of these biomarkers into clinical utility would require large-scale prospective cohorts and randomized clinical trials in future. Based on these findings and consideration we propose an avenue to introduce methylation markers into clinical practice in near future. For future studies, multi-omics profiling on matched tissue and non-invasive cohorts along with matched cohorts of adenoma to carcinoma is indispensable to concurrently stratify CRC and find novel, robust biomarkers. Moreover, future studies should examine the timing and heterogeneity of methylation as well as the difference in methylation levels between epithelial and stromal tissues.